美沙拉嗪及双歧三联活菌制剂对慢性末端回肠炎的疗效分析  

Curative effect analysis of the bifidobacteria and mesalazine to chronic terminal ileitis

作　　者：周红宇[1] 肖蓉 朱高莉[1] 周国华[1] 陈叶青[1] 

机构地区：[1]解放军169医院暨湖南师范大学附属湘南医院消化内科,湖南衡阳421002 [2]解放军169医院暨湖南师范大学附属湘南医院神经内科,湖南衡阳421002

出　　处：《临床消化病杂志》2018年第1期34-37,共4页Chinese Journal of Clinical Gastroenterology

摘　　要：[目的]总结分析美沙拉嗪及双歧三联活菌制剂对慢性末端回肠炎的疗效。[方法]将2010-01—2013-12期间确诊的264例慢性末端回肠炎患者随机分为A组、B组、C组。A组:采用马来酸曲美布汀+双歧三联活菌治疗;B组:采用马来酸曲美布汀+美沙拉嗪治疗;C组:采用马来酸曲美布汀+双歧三联活菌+美沙拉嗪治疗。疗程均为12周。观察各组疗效并进行对比分析。[结果](1)消化道症状,各组患者的症状均明显好转,A组、B组、C组的有效率分别为77.0%、76.5%、93.2%,A组与B组比较差异无统计学意义,但A组、B组与C组比较均差异有统计学意义(P<0.05),C组疗效明显优于A、B组。(2)内镜下表现:治疗后A组、B组、C组内镜下有效率分别为71.0%、72.9%、93.2%,A组与B组比较差异无统计学意义,但A组、B组与C组比较均差异有统计学意义(P<0.05),C组疗效明显优于A、B组。(3)病理组织学改变:各组治疗后组织学炎症评分与治疗前比较均差异有统计学意义(P<0.05),A组与B组比较差异无统计学意义,但A组、B组与C组比较均差异有统计学意义(P<0.05)。C组疗效明显优于A、B组。[结论]美沙拉嗪及双歧三联制剂对慢性末端回肠炎均有疗效,两者联用效果优于单药使用。[Objective]To investigate the curative effect of the salad diazoxide and bifid triple viable bacteria to chronic terminal ileitis（CTI）. [Methods]The totals of 264 patients of CTI were randomly divided into three groups, group A were treated with trimebutine maleate＋ bifidobacteria, group B were treated with Trimebutine maleate＋mesalazine, group C were treated with trimebutine maleate＋ bifidobacteria＋masalazine. Course of treatment was 12 weeks. Before and after treatment all patients were grading with clinical symptom and endscopic changes and histopathological score. [Results]（1）Digestive tract symptom： three groups＇symptom were improved, the effective rates were 77.0%, 76.5%, 93.2% respectively, compared with before treatment,the difference was statistically significant（P〈0.05）,the difference wasn＇t significant between A and B group（P〉0. 05）. But comparing with C,the two groups showed significant difference（P〈0.05）. （2）Endoscopic changes curative effect：the effective rates were 71.0% ,72.9% ,93.2% respectively, the difference wasn＇t statistically significant between A and B group （P〉0.05）, But comparing with C, the two groups showed significantly difference（P〈0.05）. （3）Histopathological score：compared with those before treatment, all the groups showed significant improvement （P〈0.05）, the difference wasn＇t significant between A and B group（P〉0.05） ,But comparing with C,the two groups showed significant difference（P〉0. 05）. the two medicines is better [Conclusion]Mesalazine and bifidobacteri are effective for CTI. Combination of than single medicine.

关 键 词：慢性末端回肠炎 美沙拉嗪 双歧三联活菌制剂 病理炎症评分 

分 类 号：R516.1[医药卫生—内科学]